Royal Bank of Canada
ARLZ

Royal Bank of Canada’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Royal Bank of Canada’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-643
Closed – – 7283
2018
Q2 		$0 Sell
643
-3,037
-83% -$2.49K ﹤0.01% 7111
2018
Q1 		$5K Sell
3,680
-826
-18% -$1.44K ﹤0.01% 5970
2017
Q4 		$6K Buy
4,506
+1,548
+52% +$2.54K ﹤0.01% 6059
2017
Q3 		$7K Sell
2,958
-30
-1% -$40 ﹤0.01% 6380
2017
Q2 		$4K Sell
2,988
-278
-9% -$402 ﹤0.01% 6159
2017
Q1 		$6K Sell
3,266
-2,888
-47% -$10.9K ﹤0.01% 6194
2016
Q4 		$27K Buy
6,154
+960
+18% +$4.56K ﹤0.01% 5612
2016
Q3 		$25K Buy
5,194
+1,621
+45% +$7.39K ﹤0.01% 5470
2016
Q2 		$12K Buy
3,573
+369
+12% +$1.39K ﹤0.01% 5705
2016
Q1 		$11K Buy
+3,204
New +$16.5K ﹤0.01% 5722

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Royal Bank of Canada's ARLZ Position: Q3 2018 in Review

Royal Bank of Canada sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 643 shares.

Royal Bank of Canada first reported a position in ARLZ in Q1 2016 and held it in 10 quarters. The position peaked at $27K in Q4 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • Royal Bank of Canada reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Royal Bank of Canada sold 643 Aralez Pharmaceuticals Inc. shares in Q3 2018.
  • Royal Bank of Canada first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 10 quarters.
  • Royal Bank of Canada's Aralez Pharmaceuticals Inc. position peaked at $27K in Q4 2016.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Royal Bank of Canada's 13F filing for Q3 2018, filed 14 Nov 2018.